Synspira Therapeutics, which is developing an inhaled therapy for cystic fibrosis, has announced the appointment of Robert Gallotto as President and CEO. Gallotto was most recently President and co-founder of Alcresta Therapeutics. He previously co-founded Allena Pharmaceuticals and served in executive positions at Alnara Pharmaceuticals, Altus Pharmaceuticals, and Sage Biopharma.
Synspira says that it plans to begin Phase 2 trials of its SNSP113 inhaled glycopolymer later this year. According to the company, SNSP113 improves mucus transport, reduces the ability of biofilms to cohere, and increases the permeability of bacterial cell walls.
Synspira Chairman of the Board William Wiesmann said, “Bob is an accomplished pharmaceutical executive, with a 30-year record of success building companies focused in cystic fibrosis and other rare diseases. His experience in development, commercialization, fundraising and driving strategic partnerships uniquely fits the needs of Synspira. Bob is a passionate patient advocate and has been involved with several successful collaborations with the CF Foundation.”
Gallotto commented, “I am very pleased to join Synspira at this very exciting time, as we build a company focused on developing transformative products for people with cystic fibrosis and other rare diseases, starting with our lead program, SNSP113. SNSP113 represents a potentially new class of therapies, designed to target the underlying cascade of events that lead to progressive pulmonary disease or other life-threatening pulmonary conditions. I look forward to working with the Synspira team and investors, as well as our partners and the patient community, in order to deliver on the promise of SNSP113 — to change the course of life-threatening progressive pulmonary diseases.”
Read the Synspira press release.
